Author

Alexandru Iacob

Observed institution: Allergan (United States)

ORCID: 0000-0001-5274-0017

Observed ORCID: 0000-0001-5274-0017

OpenAlex ID: A5076825624

Overall safety of relamorelin in adults with diabetic gastroparesis: Analysis of phase 2a and 2b trial data

2020 · Michael Camilleri, Anthony Lembo, et al. · Alimentary Pharmacology & Therapeutics · 41

Overall Safety and Tolerability of Relamorelin in Adults With Diabetic Gastroparesis: Analysis of Phase 2a and Phase 2b Trial Data

2018 · Michael Camilleri, Anthony Lembo, et al. · The American Journal of Gastroenterology · 2

IMPAACT 2041: Designing the Study of Glecaprevir/Pibrentasvir Treatment During Pregnancy

2026 · Ravi Jhaveri, Kristina M Brooks, et al. · Open Forum Infectious Diseases

Efficacy and Safety of Glecaprevir/Pibrentasvir in Participants with Chronic HCV Infection and Comorbidities or Multiple Concomitant Medications: An Integrated Analysis

2026 · Curtis Cooper, Shweta A. Raina, et al. · Infectious Diseases and Therapy

WED-264 Glecaprevir/pibrentasvir in chronic HCV: an integrated analysis of patients on concomitant opioids, antipsychotics and cardiovascular medications

2025 · Curtis Cooper, Shweta Raina, et al. · Journal of Hepatology

4550 Financial toxicity in breast cancer patients treated with radiation therapy - a cross-sectional study

2025 · Monica E. Chirila, Renata Zahu, et al. · Radiotherapy and Oncology

Clinical Outcomes for Nasopharyngeal Cancer in Non-Asian Patients: A Single-Center Experience

2025 · Renata Zahu, Daniela Urian, et al. · Journal of Clinical Medicine

3136: Clinical outcomes for nasopharyngeal cancer in a non-Asian patient population

2024 · Renata Zahu, Daniela Urian, et al. · Radiotherapy and Oncology

Works count: 8

Citation count: 43

H-index: 2

I10-index: 1